SCHEMBL16701769

SCHEMBL16701769

C=CC(=O)N(CCn1nc(-c2ccc(F)c(NC)c2)c2c(N)ncnc21)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.57
BTK Q06187 5/20 0.57
LCK P06239 2/20 0.57
JAK3 P52333 2/20 0.57
ITK Q08881 2/20 0.57
PIK3CD O00329 9/20 0.50
FGFR1 P11362 4/20 0.47
FGFR4 P22455 3/20 0.47
FGFR2 P21802 3/20 0.47
FGFR3 P22607 3/20 0.47
PIK3CA P42336 7/20 0.46
PIK3CB P42338 7/20 0.46
PIK3CG P48736 7/20 0.46
PRKDC P78527 7/20 0.46
KDR P35968 6/20 0.46
ABL1 P00519 4/20 0.46
HCK P08631 4/20 0.46
SRC P12931 4/20 0.46
MTOR P42345 4/20 0.46
EPHB4 P54760 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16701746 0.89 EGFR (0.58) EGFRBTKLCKJAK3ITK
SCHEMBL16701960 0.89 EGFR (0.58) EGFRBTKLCKJAK3ITK
SCHEMBL16702280 0.89 EGFR (0.55) EGFRBTKLCKJAK3ITK
SCHEMBL16701925 0.89 PIK3CD (0.63) EGFRBTKLCKJAK3ITK
SCHEMBL16701959 0.87 PIK3CD (0.49) EGFRBTKLCKJAK3ITK
SCHEMBL16701646 0.86 BTK (0.59) EGFRBTKLCKJAK3ITK
SCHEMBL16701594 0.85 EGFR (0.47) EGFRBTKLCKJAK3ITK
SCHEMBL16701814 0.85 FLT3 (0.47) EGFRBTKLCKJAK3ITK
SCHEMBL16701509 0.85 EGFR (0.61) EGFRBTKLCKJAK3ITK
SCHEMBL16702256 0.84 EGFR (0.61) EGFRBTKLCKJAK3ITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160272645-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-22 US claimed
WO-2015069441-A1 PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-14 WO claimed
US-20160272645-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-22 US disclosed
US-20160272645-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2016-09-22 US disclosed
WO-2015069441-A1 PYRAZOLO-, IMIDAZOLO- AND PYRROLO-PYRIDINE OR -PYRIMIDINE DERIVATIVES AS INHIBITORS O BRUTONS KINASE (BTK) MEDIVATION TECHNOLOGIES, INC. (US) 2015-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272645-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB EGFR 828/4885BTK 1/4885LCK 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.